TrialLeukemia2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Hartmut Goldschmidt et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this paperpooled ittrialcites it